Full Press Release Details
two year pulsar trial results for aflibercept 8 mg demonstrate durable vision gains at extended dosing intervals in wet age related macular degeneration.
REGN
two year pulsar trial results for aflibercept 8 mg demonstrate durable vision gains at extended dosing intervals in wet age related macular degeneration
Key Takeaway: two year pulsar trial results for aflibercept 8 mg demonstrate durable vision gains at extended dosing intervals in wet age related macular degeneration